Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cisplatin, Cytarabine, Rituximab in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved cisplatin in combination with cytarabine, dexamethasone, and granulocyte colony stimulating factor (G-CSF) (DHAP Therapy) for reimbursement as a treatment option for the treatment of patients with relapsed Non Hodgkin Lymphoma (NHL). The regimen specification also states that rituximab should be included for treatment of CD20 positive patients.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of relapsed Non Hodgkin Lymphoma. Rituximab to be included in CD20 positive patients.